AU2022208424A1 - Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome - Google Patents

Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome Download PDF

Info

Publication number
AU2022208424A1
AU2022208424A1 AU2022208424A AU2022208424A AU2022208424A1 AU 2022208424 A1 AU2022208424 A1 AU 2022208424A1 AU 2022208424 A AU2022208424 A AU 2022208424A AU 2022208424 A AU2022208424 A AU 2022208424A AU 2022208424 A1 AU2022208424 A1 AU 2022208424A1
Authority
AU
Australia
Prior art keywords
mds
tasquinimod
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022208424A
Other languages
English (en)
Other versions
AU2022208424A9 (en
Inventor
Martin BORNHÄUSER
Katja SOCKEL
Manja WOBUS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of AU2022208424A1 publication Critical patent/AU2022208424A1/en
Publication of AU2022208424A9 publication Critical patent/AU2022208424A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022208424A 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome Pending AU2022208424A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21152018.4 2021-01-18
EP21152018 2021-01-18
EP21201509.3 2021-10-07
EP21201509 2021-10-07
EP21205665 2021-10-29
EP21205665.9 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
AU2022208424A1 true AU2022208424A1 (en) 2023-08-24
AU2022208424A9 AU2022208424A9 (en) 2024-05-09

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022208424A Pending AU2022208424A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US20240091215A1 (https=)
EP (1) EP4277628B1 (https=)
JP (1) JP7837338B2 (https=)
KR (1) KR20230133317A (https=)
AU (1) AU2022208424A1 (https=)
CA (1) CA3204120A1 (https=)
ES (1) ES3057099T3 (https=)
IL (1) IL304232A (https=)
MX (1) MX2023008016A (https=)
PL (1) PL4277628T3 (https=)
WO (1) WO2022152902A1 (https=)
ZA (1) ZA202307855B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EP3711484A1 (en) * 2013-07-05 2020-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
KR20160136323A (ko) * 2014-02-28 2016-11-29 인사이트 코포레이션 골수형성이상증후군 치료용 jak1 억제제
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
MX379401B (es) * 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
EA202090655A1 (ru) * 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
JP2019127473A (ja) * 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
CA3204120A1 (en) 2022-07-21
EP4277628C0 (en) 2025-09-24
WO2022152902A1 (en) 2022-07-21
IL304232A (en) 2023-09-01
EP4277628A1 (en) 2023-11-22
JP7837338B2 (ja) 2026-03-30
KR20230133317A (ko) 2023-09-19
ZA202307855B (en) 2025-12-17
PL4277628T3 (pl) 2026-02-09
JP2024503372A (ja) 2024-01-25
ES3057099T3 (en) 2026-02-26
EP4277628B1 (en) 2025-09-24
AU2022208424A9 (en) 2024-05-09
US20240091215A1 (en) 2024-03-21
MX2023008016A (es) 2023-07-13

Similar Documents

Publication Publication Date Title
Yang et al. The mechanisms of pathological extramedullary hematopoiesis in diseases
Gonzaga et al. Mesenchymal stem cell benefits observed in bone marrow failure and acquired aplastic anemia
ES2418433T3 (es) Modulación de receptores de catecolaminas
US20120093782A1 (en) Enhanced Hematopoietic Stem Cell Engraftment
EP4277628B1 (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
EP4218768A1 (en) Combinations of imetelstat and venetoclax for use in the treatment of haematological cancer
Aljagthmi et al. Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation
JP2018521074A (ja) 幹細胞移植のための方法および組成物
WO2021173458A1 (en) Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition
KR101400900B1 (ko) 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물
US20120225028A1 (en) Compositions and methods for mobilization of stem cells
JP6339668B2 (ja) 細胞動員に使用するデキストラン硫酸
US9199028B2 (en) Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
Bao et al. Toll-like receptor 3 activator preconditioning enhances modulatory function of adipose-derived mesenchymal stem cells in a fully MHC-mismatched murine model of heterotopic heart transplantation
US12162918B2 (en) Periostin compounds for the treatment of haematological complications
CN116887844A (zh) 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐
WO2019049939A1 (en) METHODS AND COMPOSITIONS FOR PROPAGATION OF CELLS
CA2986354A1 (en) Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
Li et al. Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice
RU2454247C1 (ru) Способ профилактики острой реакции трансплантат против хозяина после трансплантации аллогенного костного мозга
WO2020017112A1 (ja) エイコサノイド産生促進剤
JP2025529143A (ja) クローン性造血を阻害するための方法および組成物
CN116509834A (zh) 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用
Soto Elevated Lactate in Acute Myeloid Leukemia (AML) Bone Marrow Microenvironment Dysfunction
KR20260030184A (ko) 인간 제대혈 cd34+ 세포로부터 제대혈 유래 골수성 억제세포의 제조방법, 상기 제조방법에 의해 제조된 제대혈 유래 골수성 억제세포 및 이의 약제학적 용도

Legal Events

Date Code Title Description
SREP Specification republished